Position
CAXTON CORP in Kyverna Therapeutics, Inc.
Back to the book · All holders of KYTX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$14.5K$9.40 → $8.63
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 18.8K | $176.5K | — | — | — | 4.1% |
| Q1 2026 | 18.8K | $162K | $8.63 | −$14.5K | −$0 | 4.0% |